ArticleNeoplasia (New York, N.Y.)2018
Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells.
Article in Neoplasia (New York, N.Y.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 22 citations in OpenAlex.
- Antitumor effects of CEP32496 on urothelial carcinoma with BRAF mutation (V595E) in dogs.Canadian journal of veterinary research = Revue canadienne de recherche veterinaire · 2026Article
- BRAF inhibitor resistance in melanoma: from resistance mechanisms to therapeutic innovations.Molecular biomedicine · 2026Review
- Second-generation BRAF inhibitor Encorafenib resistance is regulated by NCOA4-mediated iron trafficking in the drug-resistant malignant melanoma cells.Scientific reports · 2025Article
- Global trends and emerging insights in BRAF and MEK inhibitor resistance in melanoma: a bibliometric analysis.Frontiers in molecular biosciences · 2025Article
- Identification of genetic fingerprint of type I interferon therapy in visceral metastases of melanoma.Scientific reports · 2024Article
- Targeting ferroptosis in melanoma: cancer therapeutics.Cell communication and signaling : CCS · 2023Review
- Current understanding of epigenetics role in melanoma treatment and resistance.Cancer cell international · 2022Review
- A clinically annotated post-mortem approach to study multi-organ somatic mutational clonality in normal tissues.Scientific reports · 2022Article
- Sorafenib sensitizes melanoma cells to vemurafenib through ferroptosis.Translational cancer research · 2020Article
- Integrated analysis of multiple receptor tyrosine kinases identifies Axl as a therapeutic target and mediator of resistance to sorafenib in hepatocellular carcinoma.British journal of cancer · 2019Article
- Article
- The BET-bromodomain inhibitor JQ1 mitigates vemurafenib drug resistance in melanoma.Melanoma research · 2018Article
- Reversal of Resistance in Targeted Therapy of Metastatic Melanoma: Lessons Learned from Vemurafenib (BRAFCancers · 2018Review
- Targeted next-generation sequencing of 565 neuro-oncology patients at UCLA: A single-institution experience.Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BRAF is the most frequently mutated gene in melanoma. Constitutive activation of mutant BRAF
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.